Basic Filitra Information

• INN (International Nonproprietary Name): Vardenafil
• Brand Names Available In United Kingdom: Levitra and generics are authorised in the United Kingdom; Staxyn (orodispersible 10 mg) is also available; Filitra is known in online and parallel markets but is not shown as a registered UK brand.
• ATC Code: G04BE09
• Forms & Dosages: Tablets (2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg, 60 mg reported in some markets) and Orodispersible Tablet (10 mg for Staxyn).
• Manufacturers In United Kingdom: Leading suppliers for regulated markets include Bayer Plc and distributors such as GlaxoSmithKline for UK channels.
• Registration Status In United Kingdom: Levitra and vardenafil generics are authorised; Filitra is not listed in major regulatory registries for the UK and is mainly encountered via international e‑pharmacies.
• OTC / Rx Classification: Prescription Only (Rx)

Key Findings From Recent Trials

Major 2022–2025 Studies

What did clinicians want to know from the newest trials?

Randomised trials and pooled analyses between 2022 and 2025 continued to assess vardenafil within the vardenafil class as an on‑demand PDE5 inhibitor for erectile dysfunction.

Several studies compared vardenafil with sildenafil and other PDE5 inhibitors in typical outpatient populations and reported on time to onset, efficacy measures and tolerability.

Main Outcomes

Primary endpoints commonly used were International Index of Erectile Function (IIEF) domain scores and successful intercourse attempts within predefined windows such as 60–120 minutes.

Across trials, vardenafil improved IIEF scores and increased rates of successful intercourse attempts in the specified time windows.

Head‑to‑head data often reported modest but consistent faster time to erection onset for vardenafil compared with sildenafil in some patient groups.

Safety Observations

Safety findings from 2022–2025 were consistent with established PDE5 class profiles and reported mostly mild, transient adverse events.

Common events were headache, flushing and nasal congestion with low discontinuation rates.

No new class‑wide safety signals were identified in those trial periods, although rare serious events such as hypotension or priapism were documented in predisposed individuals.

Clinical implication for UK prescribers: vardenafil can be considered a rapid‑onset option among PDE5 inhibitors, but prescribers should confirm licensed products for UK practice and counsel patients on safety.

Clinical Mechanism Of Action

Layman’s Explanation

How does vardenafil help when someone has erectile dysfunction?

Vardenafil relaxes the blood vessels that supply the penis so more blood can flow in during sexual arousal and produce an erection.

It is taken as an on‑demand oral medicine under the INN vardenafil and commonly sold as Levitra or similar generics.

Scientific Breakdown

Vardenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor, classified under ATC code G04BE09.

By blocking PDE5 it prevents the breakdown of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum smooth muscle.

Higher cGMP levels sustain nitric oxide–mediated vasodilation and therefore erection when sexual stimulation is present.

PDE5 Inhibition Cascade

Sexual stimulation triggers nitric oxide release from nerve endings and endothelium.

NO increases production of cGMP in smooth muscle cells.

cGMP causes smooth muscle relaxation and increased blood inflow to the penis.

Vardenafil attenuates PDE5 activity so cGMP persists longer and the erection is maintained.

Pharmacokinetics Basics

Vardenafil is absorbed relatively rapidly with a typical onset around 60 minutes, making it suitable for on‑demand use.

Its duration is shorter than tadalafil but comparable to sildenafil for usual clinical windows of effect.

Metabolism is predominantly hepatic via CYP3A4, which explains interaction risk with CYP3A4 inhibitors and the need for dose adjustments in liver impairment.

When discussing options with patients in the UK, note the relatively faster onset of vardenafil versus sildenafil for many users.

Scope Of Approved And Off‑Label Use

United Kingdom Approvals

Which vardenafil products are authorised for use in the UK?

Vardenafil as the INN is authorised and marketed in the UK as Levitra and generics, and Staxyn is available as an orodispersible 10 mg preparation.

All vardenafil products are prescription‑only in regulated markets, including the United Kingdom.

Filitra is frequently marketed online and in some export markets, but it is not listed on major UK regulatory registries as an authorised brand.

Notable Off‑Label Trends

Clinicians sometimes receive patient enquiries about daily low‑dose use despite vardenafil being licensed for on‑demand administration only.

Long‑term fixed daily dosing is not routinely recommended for vardenafil and safety beyond typical on‑demand use is less well established.

Some patients obtain Filitra through international e‑pharmacies where strengths up to 60 mg are reported; this variation raises concerns about authenticity and safety.

MHRA and NHS pathways in the UK favour licensed brands such as Levitra and Staxyn and advise against buying unregistered imports because of counterfeiting risks.

Prescribing implication: document informed consent and confirm product provenance when patients present imported or online purchases.

Dosage Strategy

General Dosing

What dose should a man new to vardenafil start on?

The recommended initial adult dose is 10 mg taken orally about 60 minutes before sexual activity.

Dose may be adjusted to 5 mg or increased to 20 mg depending on efficacy and tolerability, with no more than one dose per 24 hours.

Vardenafil is intended for on‑demand use rather than routine daily fixed dosing.

Condition‑Specific Dosing

For moderate hepatic impairment, limit dosing to a maximum of 10 mg and do not use in severe hepatic impairment where vardenafil is contraindicated.

Mild to moderate renal impairment normally requires no dose adjustment, but in severe renal impairment (CrCl <30 mL/min) start at the lowest dose and proceed with caution.

Special Populations (Renal/Hepatic/Elderly/Paediatric)

Elderly patients do not require an automatic initial dose reduction, but frail older adults should start at the lowest effective dose.

Vardenafil is not indicated for individuals under 18 years of age.

Before prescribing in the UK, review comorbidities and interacting medicines, especially CYP3A4 inhibitors, and counsel patients on expected onset and maximum daily frequency.

Safety Protocols

Contraindications

Who must not take vardenafil?

Absolute contraindications include any concomitant nitrate therapy by any route, severe hepatic impairment, known hypersensitivity to vardenafil or excipients, and severe cardiac disorders where sexual activity is inadvisable.

Relative contraindications and precautions include conditions that predispose to priapism such as sickle cell disease, anatomical penile deformity, severe renal impairment and coadministration with alpha‑blockers or QT‑prolonging drugs.

Adverse Effects

Common side effects are usually mild and transient and include flushing, headache, nasal congestion or sinus pain, dyspepsia, dizziness and back pain.

Serious but rare events include significant hypotension, sudden vision changes, syncope and priapism; these need urgent medical assessment.

In overdose, patients are at risk of severe hypotension and prolonged erection and should seek emergency care.

Screen thoroughly for nitrate use and cardiovascular risk before prescribing and ensure patients know when to seek urgent help.

Interaction Mapping

Food Interactions

Does food change how quickly vardenafil works?

High‑fat meals can delay absorption and slow onset for oral PDE5 agents including vardenafil, so advise patients to avoid a heavy fatty meal immediately before dosing if timing is important.

Grapefruit juice and potent CYP3A4 inhibitors can increase plasma levels and the risk of adverse effects.

Drug Combinations To Avoid

Concurrent nitrate therapy is an absolute contraindication because the combination can cause severe life‑threatening hypotension.

Avoid or use extreme caution with alpha‑blockers; if coadministration is required initiate at low doses and monitor blood pressure closely.

Potent CYP3A4 inhibitors such as ritonavir or ketoconazole increase exposure and may require dose reduction or avoidance.

Drugs that prolong the QT interval should prompt assessment because vardenafil can further affect QT in susceptible patients.

Always verify current medicines including over‑the‑counter and herbal remedies and document interaction counselling in the record.

Patient Experience Analysis

Survey Data

What do patients say about vardenafil in audits and surveys?

Clinical surveys and pharmacy audits show patients value the faster onset and tolerability of vardenafil compared with some alternatives.

Patient‑reported outcomes typically include improved confidence, increased successful intercourse attempts and acceptable side‑effect burden for most users.

Forum Trends

Online forums and e‑pharmacy feedback commonly discuss sourcing questions, comparisons between 10 mg and 20 mg doses and concerns about authenticity when buying overseas.

Filitra appears frequently in forum requests but is often associated with parallel markets rather than UK authorised supply.

Many UK patients prefer obtaining licensed brands such as Levitra via NHS or private prescription to avoid counterfeit or variable‑label products.

Counselling points: set realistic expectations on onset and duration, emphasise prescription‑only supply in the UK and encourage Yellow Card reporting for adverse events.

Distribution And Pricing Landscape

How is vardenafil distributed and priced in the UK and beyond?

Vardenafil is supplied globally as Levitra, Staxyn and a variety of generics, with Bayer and large distributors serving regulated markets.

Filitra is distributed mainly through certain e‑pharmacies and manufacturers in India such as Fortune Health Care and Centurion Remedies and is more common in parallel markets.

In the UK, licensed Levitra and generics dominate authorised channels and pricing varies by brand, pack size and dispensing route (NHS, private clinic, registered online pharmacy).

Parallel imports and unregulated suppliers sometimes list Filitra at lower prices, but quality assurance, registration and batch traceability are often unclear.

Clinicians should steer patients towards MHRA‑authorised suppliers and warn against unverified imports because of counterfeiting, incorrect dosing and legal issues.

Note: in our online pharmacy, filitra is available without a prescription with discreet delivery to United Kingdom in 5‑14 days; patients are reminded that unregistered imports carry safety and regulatory risks.

Alternative Options

Comparison Table (Narrative)

Which PDE5 alternative best fits a particular patient's needs?

Sildenafil (Viagra/generics), tadalafil (Cialis/generics) and avanafil (Spedra/Stendra) are the main comparators to vardenafil available in the UK market.

Vardenafil generally offers a faster onset than sildenafil and a shorter duration than tadalafil, while avanafil is marketed for very rapid onset with a favourable tolerability profile in some studies.

Pros And Cons

• Vardenafil (Filitra as market variant): Pro — rapid onset useful for planned activity; Con — Filitra is not registered in major UK registries and there are interaction and contraindication considerations.
• Sildenafil: Pro — well established and widely available; Con — onset may be slower for some users compared with vardenafil.
• Tadalafil: Pro — long duration (up to 36 hours) and daily dosing option; Con — longer exposure to adverse effects if they occur.
• Avanafil: Pro — marketed for rapid onset and good tolerability; Con — less long‑term real‑world data compared with older agents.

Choice should be individualised based on timing preference, comorbidity, concomitant medication and product legitimacy.

Regulatory Status

Is Filitra regulated the same way as Levitra?

Vardenafil is authorised in many regulated markets as Levitra, Staxyn and generics under ATC code G04BE09.

Filitra as a brand is not listed in major authoritative regulatory registries and tends to appear primarily via international e‑pharmacies and parallel markets rather than EMA/MHRA authorised channels.

In the UK, vardenafil products are prescription‑only and should be supplied via MHRA‑authorised routes; vendors selling Filitra without UK registration present regulatory and safety concerns.

Practitioners should verify licence status, batch labelling and import legality when patients present medications sourced abroad and report suspected counterfeit products to the MHRA Yellow Card scheme.

Consolidated FAQ

Q: Is Filitra the same as Levitra?

A: Filitra and Levitra both contain vardenafil as the INN, but Filitra is not registered in many regulated registries while Levitra and Staxyn are authorised UK brands.

Q: How quickly does it work?

A: Typical onset is around 60 minutes, with many users reporting a faster onset than sildenafil.

Q: What dose should I start?

A: Standard initial dose is 10 mg taken about 60 minutes before activity; adjust between 5 mg and 20 mg according to response; do not exceed once daily.

Q: Can I take nitrates?

A: No — concurrent nitrate therapy is an absolute contraindication.

Q: Is it safe to buy Filitra online?

A: Buying Filitra from unverified sellers is risky; patients should verify MHRA authorisation for UK supply and avoid unregistered imports.

Q: Any dose changes for liver/kidney problems?

A: Moderate hepatic impairment — maximum 10 mg; severe hepatic impairment — contraindicated; severe renal impairment — start at lowest dose and use caution.

Visual Guide

Suggested Diagrams

Which visuals help explain vardenafil quickly?

1) Mechanism flowchart: Sexual Stimulation → Nitric Oxide → cGMP → PDE5 Inhibition (Vardenafil) → Erection.

2) Onset/duration timeline comparing vardenafil, sildenafil, tadalafil and avanafil with annotated typical onset and useful time windows.

3) Contraindication decision tree: Nitrates? Cardiovascular Risk? Hepatic Impairment? → Do Not Prescribe or Consider Alternatives.

Infographic Elements

Include callouts for UK regulatory status (MHRA/NHS), a prescription‑only symbol, a dosing ladder (5 → 10 → 20 mg), boxed safety alerts (nitrates, priapism, CYP3A4 interactions) and a manufacturer/brand map noting Levitra/Staxyn versus Filitra export channels such as Fortune Health Care and Centurion Remedies.

Design with icons for time (onset), shield (safety) and pharmacy (authorised supply) for rapid clinician and patient comprehension.

Storage And Transport

How should vardenafil be stored and what are transport risks?

Store vardenafil tablets at room temperature, typically 20°–25°C, in original packaging away from light and moisture.

Follow manufacturer labelling for orodispersible formulations and keep blister integrity intact for Staxyn or similar products.

International shipping from unregulated e‑pharmacies can expose products to temperature extremes and prolonged transit that may degrade potency and complicate batch traceability.

For UK dispensing, source from MHRA‑authorised wholesalers and confirm batch numbers and expiry dates on arrival.

Document storage location, maintain stock rotation and escalate any returned or suspicious batches to pharmacy governance and the MHRA for investigation.

Guidelines For Proper Use

Prescriber Checklist

What should prescribers confirm before issuing vardenafil?

Confirm the diagnosis of erectile dysfunction and review cardiovascular status and the patient’s ability to undertake sexual activity.

Check concurrent medicines including nitrates, alpha‑blockers and CYP3A4 inhibitors and assess hepatic and renal function plus age and frailty.

Record discussion about on‑demand use, dosing (start 10 mg, adjust 5–20 mg), maximum frequency (once daily) and verify product legitimacy, particularly when patients present imported Filitra.

Document informed consent and plan follow‑up for efficacy and tolerability.

Patient Counselling Points

Explain expected onset around 60 minutes and advise avoiding a heavy fatty meal immediately before dosing to reduce delay in onset.

Warn about the absolute contraindication with nitrates and describe common mild side effects such as flushing, headache, nasal congestion, dyspepsia, dizziness and back pain.

Tell patients which symptoms require urgent care: erection lasting longer than four hours, sudden vision loss or severe hypotension.

Encourage reporting adverse events through the MHRA Yellow Card scheme and returning to the prescriber for dose review if efficacy or tolerability is suboptimal.

Delivery Across United Kingdom

Final Notes For Clinicians And Patients

Vardenafil is a well‑established PDE5 inhibitor offering relatively rapid onset for on‑demand treatment of erectile dysfunction.

Prefer licensed UK brands such as Levitra or Staxyn when prescribing or dispensing and advise patients against unregulated imports of Filitra because registration status and batch traceability are unclear.

Screen for nitrates, assess cardiovascular risk and review concomitant medicines especially CYP3A4 inhibitors and alpha‑blockers before starting treatment.

Provide written dosing instructions, set realistic expectations for onset and duration and arrange follow‑up to review efficacy and tolerability.

Report adverse reactions and suspected counterfeit products to the MHRA Yellow Card scheme and escalate supply concerns to pharmacy governance as required.